Nephrogenic systemic fibrosis in a Chinese renal-transplant recipient

Chan, Kakit; Tang, W. Y. M.; Hau, Kai-Ching; W, Lam; Lam, H.; Kwan, Tze-Hoi; Lo, K. K.

doi:10.1111/j.1365-2230.2008.02764.x

Cited by 6 publications

(1 citation statement)

References 3 publications

(3 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most NSF cases have been reported in the USA and Europe. There are only a few Asian cases reported in the English literature [16][17][18][19], despite approximately 20% of GBCAs in the world being used in Japan (personal communication with employees of Daiichi Sankyo, Tokyo, Japan; Bayer Yakuhin, Osaka, Japan; Eisai, Tokyo, Japan). It has been suggested that there is no race difference in NSF occurrence [1,12].…”

mentioning

confidence: 99%

Nephrogenic systemic fibrosis: risk factors suggested from Japanese published cases

Tsushima

Kanal²,

Thomsen³

2010

BJR

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Nephrogenic systemic fibrosis: risk factors suggested from Japanese published cases

Tsushima

Kanal²,

Thomsen³

2010

BJR

View full text Add to dashboard Cite

show abstract

Risk factors for NSF: A literature review

Prince

Zhang

Roditi

et al. 2009

Magnetic Resonance Imaging

109

View full text Add to dashboard Cite

Emerging evidence linking gadolinium-based contrast agents (GBCAs) to nephrogenic systemic fibrosis (NSF) has changed medical practice patterns toward forgoing GBCA-enhanced magnetic resonance imaging (MRI) or substituting other imaging methods, which are potentially less accurate and often radiation-based. This shift has been based on reports of high NSF incidence at sites where a confluence of risk factors occurred in patients with severe renal dysfunction. This review article explores the factors that affect NSF risk, compares risks of alternative imaging procedures, and demonstrates how risk can be managed by careful selection of GBCA dose, timing of injection with respect to dialysis, and other factors. Nearly half of NSF cases are a milder form that does not cause contractures or reduce mobility. It appears that eliminating even a single risk factor can reduce NSF incidence/risk at least 10-fold. Elimination of multiple risk factors by using single-dose GBCA, dialyzing dialysis patients quickly following GBCA administration, avoiding GBCA in acute renal failure while serum creatinine is rising, and avoiding nonionic linear GBCA in renal failure patients may reduce NSF risk more than a thousand-fold, thereby allowing safe GBCA-enhanced MRI in virtually all patients.

show abstract

Nephrogenic Systemic Fibrosis

Zou

Zhang

Roditi

et al. 2011

JACC: Cardiovascular Imaging

View full text Add to dashboard Cite

Discovery of an association between gadolinium-based contrast agents (GBCAs) and nephrogenic systemic fibrosis (NSF) has led to less use of GBCA-enhanced magnetic resonance imaging in dialysis patients and patients with severe renal failure at risk of NSF, and the virtual elimination of new cases of NSF. But shifting patients with renal failure to alternative imaging methods may subject patients to other risks (e.g., ionizing radiation or iodinated contrast). This review paper examines 370 NSF cases reported in 98 articles to analyze NSF risk factors. Eliminating multiple risk factors by limiting GBCA dose to a maximum of 0.1 mmol/kg, dialyzing patients undergoing dialysis quickly following GBCA administration, delaying GBCA in acute renal failure until after renal function returns or dialysis is initiated, and avoiding nonionic linear GBCA in patients with renal failure especially when there are proinflammatory conditions may substantially reduce the risk of NSF.

show abstract

Nephrogenic systemic fibrosis in a Chinese renal-transplant recipient

Cited by 6 publications

References 3 publications

Nephrogenic systemic fibrosis: risk factors suggested from Japanese published cases

Nephrogenic systemic fibrosis: risk factors suggested from Japanese published cases

Risk factors for NSF: A literature review

Nephrogenic Systemic Fibrosis

Contact Info

Product

Resources

About